Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

A new partnership has been formed between the Universities of Oxford and Birmingham to speed up the development of novel treatments for arthritis, supported by a £7 million investment from the Kennedy Trust for Rheumatology Research.

Drug development Sisacorn - Shutterstock

A new partnership to speed up the development of novel treatments for arthritis has been launched, supported by a £7 million investment from the Kennedy Trust for Rheumatology Research.

The partnership between the Universities of Oxford and Birmingham will be based at the Kennedy Institute of Rheumatology at Oxford and the Institute of Translational Medicine in Birmingham.  It will harness the existing research strengths of both universities in order to accelerate the development and testing of new therapies for patients. The Arthritis Therapy Acceleration Programme (A-TAP) will develop and test therapies based on the underlying causes of inflammatory disease, rather than simply treating the clinical symptoms.

Read more